At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
Selonsertibdrug
Likely dose
Selonsertib 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function
In Brief
A Phase 1 clinical trial evaluating Selonsertib for Diabetic Kidney Disease. Completed, enrolled 52 participants across 5 sites.
Detailed Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Kidney Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedJul 28, 2015
Enrollment StartAug 18, 2015
Primary CompletionDec 15, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.9 years ago
Interventions
Selonsertibdrug
6 mg tablets administered orally in fed state